As Eli Lilly advances its ambitious USD 27 billion investment plan to establish four new manufacturing facilities in the United States, the company has confirmed plans to sell its existing production site in Branchburg, New Jersey—a facility that has faced regulatory scrutiny in the past.

The decision is part of a broader overhaul of Lilly’s manufacturing strategy, aimed at building capacity for next-generation therapies. “We have a long-term plan to deliver big bets on next-gen modalities, and we are currently leading the largest manufacturing expansion in Lilly’s history,” a company spokesperson stated. “Following a comprehensive assessment, we are repositioning our manufacturing operations to our new facilities to optimize future flexibility for our evolving pipeline.”

The confirmation follows the announcement earlier this year of Lilly’s massive expansion strategy, which includes the development of three plants dedicated to active pharmaceutical ingredient (API) manufacturing and one facility focused on injectable drugs. While the company has yet to disclose the exact locations of these upcoming sites, it noted in February that it is in negotiations with several U.S. states. Industry speculation suggests that Houston could be a potential location for one of the API facilities.

The expansion is expected to generate more than 3,000 new jobs in the U.S. Eli Lilly plans to announce the selected locations later this year, with all facilities expected to be operational within five years.